Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1

Conditions

Neoplasms 17Carcinoma, Non-Small-Cell Lung 11Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Breast Neoplasms 3Head and Neck Neoplasms 2Glioblastoma 2Thrombocytosis 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Oligodendroglioma 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mouth Neoplasms 1Meningioma 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × Afatinib × Clear all
NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Boehringer Ingelheim

Phase 1 Completed
13 enrolled 11 charts
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.

Boehringer Ingelheim

Phase 1 Completed
18 enrolled 14 charts
Breast

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔